VectivBio’s $110 Million Crossover Financing


Walder Wyss advised BPI France, Cowen Healthcare Investments, Novo Ventures, OrbiMed and Versant Ventures as lead investors, while Homburger advised VectivBio.

VectivBio AG announced that it has closed a USD 110 m crossover financing from new investors Surveyor Capital (a Citadel company), Cormorant Capital and Eventide Asset Management, with participation from existing investors Versant Ventures, OrbiMed, Novo Holdings, BPI France, Tekla Healthcare Investors, Inserm Transfert Initiative and Cowen Healthcare Investments.

VectivBio AG is a clinical-stage biotechnology company developing transformational medicines for patients with serious rare diseases.

Proceeds from the financing will be used to support the Phase III program of VectivBio’s lead investigational product, apraglutide, to treat shoProceeds from the financing will be used to support the Phase III program of VectivBio’s lead investigational product, apraglutide, to treat short bowel syndrome (SBS), early commercialization activities and further development of the pipeline through business development initiatives.

The Homburger team was led by Andreas Müller (Picture) and included Margrit Marti, Angela Oppliger, Mirko Stiefel, Carolina Rodriguez, Luca Dal Molin, Kirsten Schmidt. Stefan Oesterhelt, Joël Gyger and Raphaël Fellay.

The Walder Wyss team included Alexander Gutmans and Karina Tschon.

Involved fees earner: Luca Dal Molin – Homburger; Raphaël Fellay – Homburger; Joël Gyger – Homburger; Margrit Marti – Homburger; Andreas Müller – Homburger; Stefan Oesterhelt – Homburger; Angela Oppliger – Homburger; Kirsten Schmidt – Homburger; Mirko Stiefel – Homburger; Alexander Gutmans – Walder Wyss Ltd.; Karina Tschon – Walder Wyss Ltd.;

Law Firms: Homburger; Walder Wyss Ltd.;

Clients: Bpifrance; Cowen Healthcare Investments; Novo Holdings A/S; OrbiMed; VectivBio AG; Versant Ventures;